Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Stacy L. Moulder"'
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Autor:
Jianying Zhou, Tejaswini P. Reddy, Hongbin Wang, Stacy L. Moulder, Wei Qian, Roberto R. Rosato, Jenny C. Chang, Helen Piwnica-Worms, Liliana Guzman
Publikováno v:
Cancer Research. 81:PS11-17
Metaplastic breast cancer (MpBC) is a rare subset accounting for less than 1% of all breast cancers. MpBC exhibits the worst prognosis in comparison to triple-negative breast cancer (TNBC) with a dismal poor survival rate in patients with metastatic
Autor:
Emi Sei, Stephen Y. Lai, Shanshan Bai, Nicholas Navin, Alexander Davis, Fang Wang, Aislyn Schalck, Ken Chen, Tapsi Kumar, Ying C. Henderson, Min Hu, Ruli Gao, Yiyun Lin, Yun Yan, Stacy L. Moulder, Simona F. Shaitelman, Jennifer Wang
Publikováno v:
Nature biotechnology
Single-cell transcriptomic analysis is widely used to study human tumors. However, it remains challenging to distinguish normal cell types in the tumor microenvironment from malignant cells and to resolve clonal substructure within the tumor. To addr
Autor:
Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Hamy, Marick Laé, Fabien Reyal, Gabe S Sonke, Tessa G Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martín, Maria del Monte-Millán, Sara López-Tarruella, Judy C Boughey, Matthew P Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Stephen B Edge, Jean E Abraham, John M S Bartlett, Carlos Caldas, Janet Dunn, Helena Earl, Larry Hayward, Louise Hiller, Elena Provenzano, Stephen-John Sammut, Jeremy S Thomas, David Cameron, Ashley Graham, Peter Hall, Lorna Mackintosh, Fang Fan, Andrew K Godwin, Kelsey Schwensen, Priyanka Sharma, Angela M DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J van 't Veer, Laura J Esserman, W Fraser Symmans, Kathi Adamson, Kathy S. Albain, Adam L. Asare, Smita M. Asare, Ron Balassanian, Heather Beckwith, Scott M. Berry, Donald A. Berry, Judy C. Boughey, Meredith B. Buxton, Yunn-Yi Chen, Beiyun Chen, A. Jo Chien, Stephen Y. Chui, Amy S. Clark, Julia L. Clennell, Brian Datnow, Angela M. DeMichele, Xiuzhen Duan, Kirsten K. Edmiston, Anthony D. Elias, Erin D. Ellis, Laura L. Esserman, David M. Euhus, Oluwole Fadare, Michael D Feldman, Andres Forero-Torres, Barbara B. Haley, Hyo S. Han, Shuko Harada, Patricia Haugen, Teresa Helsten, Gillian L. Hirst, Nola M. Hylton, Claudine Isaacs, Kathleen Kemmer, Qamar J. Khan, Laila Khazai, Molly E. Klein, Gregor Krings, Julie E. Lang, Lauren G. LeBeau, Brian Leyland-Jones, Minetta C. Liu, Shelly Lo, Janice Lu, Anthony Magliocco, Jeffrey B. Matthews, Michelle E. Melisko, Paulette Mhawech-Fauceglia, Stacy L. Moulder, Rashmi K. Murthy, Rita Nanda, Donald W. Northfelt, Idris T. Ocal, Olufunmilayo Olopade, Stefan Pambuccian, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Garry Peterson, Mara Rendi, Hope S. Rugo, Sunati Sahoo, Sharon Sams, Ashish Sanil, Husain Sattar, Richard B. Schwab, Ruby Singhrao, Katherine Steeg, Erica Stringer-Reasor, W. Fraser Symmans, Ossama Tawfik, Debasish Tripathy, Megan L. Troxell, Laura J. van't Veer, Sara J. Venters, Tuyethoa Vinh, Rebecca K. Viscusi, Anne M. Wallace, Shi Wei, Amy Wilson, Douglas Yee, Jay C. Zeck
Publikováno v:
I-SPY 2 Trial Consortium 2022, ' Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients ', The Lancet Oncology, vol. 23, no. 1, pp. 149-160 . https://doi.org/10.1016/S1470-2045(21)00589-1
The Lancet. Oncology, vol 23, iss 1
The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group
The Lancet. Oncology, vol 23, iss 1
The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group
Background: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b5a03d8d05046179f5dcc364471bd0
https://research.vumc.nl/en/publications/4b35d135-33e6-4bf5-982e-dab0f5ddbfd8
https://research.vumc.nl/en/publications/4b35d135-33e6-4bf5-982e-dab0f5ddbfd8
Autor:
Helen Piwnica-Worms, Jennifer K. Litton, Banu Arun, Beatriz E. Adrada, Haven R. Garber, Gaiane M. Rauch, Debu Tripathy, Senthil Damodaran, Elizabeth A. Mittendorf, Vicente Valero, Rashmi Krishna Murthy, Fraser Symmans, Stacy L. Moulder, Lei Huo, Alastair M. Thompson, Naoto T. Ueno, Nuhad K. Ibrahim, Rosalind P. Candelaria, Bora Lim
Publikováno v:
Cancer Research. 80:P2-16
BACKGROUND: Current treatment for early stage triple negative breast cancer (TNBC) includes neoadjuvant systemic chemotherapy (NAST), which is used to assess disease biology and the need for adjuvant treatment in case of residual disease at the time
Autor:
Gordon Broderick, Eileen H. Shinn, Bryan Fellman, Ainslee Johnson, Elizabeth Wieland, William Fraser Symmans, Stacy L. Moulder
Publikováno v:
JCO Clinical Cancer Informatics
PURPOSE Nearly 40% of patients with breast cancer discontinue their adjuvant oral endocrine treatment (ET). We measured discontinuation rates of ET at a comprehensive cancer center. We then used an iterative approach to model patterns of determinants
Autor:
Paul Haluska, Melanie Catherine Majure, Denise M. Wolf, Rachel L. Yung, Paula R. Pohlmann, Hyo S. Han, Jeffrey B. Matthews, Michelle E. Melisko, A. Jo Chien, Andres Forero-Torres, Kristen K. Edmiston, Adam Asare, Hope S. Rugo, Laura J. van't Veer, Jane Perlmutter, Debu Tripathy, Gillian L. Hirst, Anne M. Wallace, Patricia A. Robinson, Rita A. Mukhtar, Julia L. Clennell, W. Fraser Symmans, Judy C. Boughey, Scott M. Berry, Douglas Yee, Rita Nanda, Claudine Isaacs, Anthony D. Elias, Christina Yau, Julia Wulfkuhle, Nola M. Hylton, Emanuel F. Petricoin, Karthik V. Giridhar, Ashish Sanil, Smita Asare, Barbara Haley, Lajos Pusztai, Heather Beckwith, Laura J. Esserman, Kathleen Kemmer, Erin D. Ellis, Lamorna Brown-Swigart, Meredith Buxton, Stacy L. Moulder, Melissa Paoloni, Teresa Helsten, Donald A. Berry, Carla I. Falkson, Kathy S. Albain, Amy S. Clark, Angela DeMichele, Erica Stringer-Reasor, Qamar J. Khan, Amy Wilson, Ruby Singhrao
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
NPJ breast cancer, vol 7, iss 1
NPJ Breast Cancer
NPJ breast cancer, vol 7, iss 1
NPJ Breast Cancer
I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal an
Autor:
Meghan Sri Karuturi, Tara Sanft, Denise A. Yardley, Angela DeMichele, Sibel Blau, Sara A. Hurvitz, Hope S. Rugo, Amy S. Clark, Amelia Zelnak, Aditya Bardia, Das Purkayastha, Cynthia X. Ma, Lowell L. Hart, Stacy L. Moulder
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose: Standard-of-care treatment for metastatic hormone receptor–positive (HR+), HER2-negative (HER2−) breast cancer includes endocrine therapy (ET) combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Optimal treatment after progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d10c70a51cc377dfe2b31a20be89ec
https://escholarship.org/uc/item/0mj128b0
https://escholarship.org/uc/item/0mj128b0
Autor:
Eleni Lagkadinou, Markus Joerger, Sara A. Hurvitz, Andrea Varga, Oliver Boix, Christine Rentzsch, Apostolia Maria Tsimberidou, Andreas Schneeweiss, Stacy L. Moulder, Matthias Ocker, Silke Thiele, Gary Wilkinson, Marion Rudolph, Dagmar Hess, Cynthia X. Ma
Publikováno v:
Cancers, vol 11, iss 12
Cancers
Volume 11
Issue 12
Cancers
Volume 11
Issue 12
This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e7672e0843827dd4b68b896f8dec21
https://escholarship.org/uc/item/3fn83958
https://escholarship.org/uc/item/3fn83958
Autor:
Ricardo H. Alvarez, Vicente Valero, Banu Arun, Gabriel N. Hortobagyi, Nuhad K. Ibrahim, Debu Tripathy, Diane Liu, Naoto T. Ueno, Marc Uemura, Wendy Woodward, Bora Lim, Kanwal Pratap Singh Raghav, John Thomas French, Kenneth R. Hess, Bisrat G. Debeb, Stacy L. Moulder
Publikováno v:
Cancer. 124:2299-2305
Background Inflammatory breast cancer (IBC) is associated with a poor prognosis and high risk of central nervous system (CNS) metastases. Methods We retrospectively reviewed stage III-IBC patients compared with noninflammatory invasive ductal carcino